Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
Lilly announced its data lineup for the 2026 ESMO Congress (October 23-27, Madrid), with presentations across its oncology portfolio including rapid oral sessions for sofetabart mipitecan and olomorasib. First Phase 1 data for Sofe-M, Lilly's FRα-targeting ADC, in platinum-sensitive ovarian cancer supports the ongoing Phase 3 FRAmework-01 trial, and updated first-line data for olomorasib in KRAS G12C-mutant NSCLC support its Phase 3 SUNRAY-01 program. Updated Phase 3 data for Retevmo in RET-mutant medullary thyroid cancer and overall survival data for Verzenio from the postMONARCH trial will also be presented.
Key figures
- Kras g12c nsclc prevalence
- 13%
- Olomorasib target occupancy
- >90%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.